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The internal alpha particle beam of the heavy ion cyclotron operated by the Heavy Ion Laboratory (HIL) of
the University of Warsaw has a maximum energy of 32 MeV and currently an intensity of up to 1 pµA. This beam is
used by the HIL-University of Silesia collaboration for the production of research quantities of 211At, 72Se/72As and
43,44Sc radioisotopes. The produced activities are transported to the Institute of Nuclear Chemistry and Technology
in Warsaw where research on therapeutic and imaging radiopharmaceuticals based on these radioisotopes is pursued.
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1. Introduction
In recent years an important part of the activity of the
Heavy Ion Laboratory (HIL), a department of the Uni-
versity of Warsaw, has been devoted to nuclear physics
applications in the life sciences, see e.g. [13]. In this pa-
per we concentrate on the production of research quanti-
ties of radioisotopes with possible future uses in nuclear
medicine employing the internal alpha particle beam of
the U200P heavy ion cyclotron, which began operation
more than twenty years ago [4]. The radioisotopes cur-
rently studied are: 211At, 72Se/72As and 44,43Sc, pro-
duced on 209Bi, natGeO2 and
natCaO targets. After the
determination of their thick target production yield, ex-
pected saturation yield and radionuclidic purity the ir-
radiated radioactive samples are transported to the In-
stitute of Nuclear Chemistry and Technology, where the
binding of these radionuclides to the various precursors
and bioconjugates is performed (see e.g. [5]).
2. Target preparation
Targets for these studies were prepared using various
techniques. The metallic Bi targets used for studying
the 209Bi(α, 2n)211At reaction were produced by direct
melting of grains of pure (5N) Bi metal onto the target
cavity in aluminium backing. The depth of the cavity
corresponds to the thickness of the target. The backing,
together with the Bi grains, was heated on a hot plate
and the molten Bi was distributed over the area of the
cavity with the help of a graphite spatula. Due to the
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use of an internal beam the target has a special shape,
i.e. one edge is frameless. Details of the Bi preparation
procedure may be found in Ref. [6].
Targets for the other two reactions, i.e.
70Ge(α, 2n)72Se and 40Ca(α,p)43Sc, were prepared
from the oxides. In both cases the appropriate amount
of the relevant oxide, i.e. natGeO2 or
natCaO, was
mixed with diluted glue and after the mixture had been
distributed over the cavity of the aluminium backing it
was left to dry. The shape of the cavity (one side open)
does not allow the application of powder sedimentation
from the diluted glue, the technique described in [7], but
this modification gave targets that were stable under
beam.
All targets were fixed to a copper holder, wrapped in
thin aluminium foil (to retain potential vapour from the
target material or pieces of it peeling off the backing) and
covered with thin copper foil for beam monitoring.
3. Targeted alpha therapy radioisotope 211At
During the last few years special attention has been
concentrated on alpha-particle emitters as therapeutic
radioisotopes. Alpha particles, thanks to their large lin-
ear energy transfer (LET α ≈ 100 keV/µm) are very
well suited to double-strand breaking of malignant cells.
Their range in tissue is 40100 µm which corresponds
to the dimension of a few cells. They are very effective
in the destruction of small tumours of a few cells in di-
mension with much lower interaction with surrounding
healthy cells, provided a vector molecule that can effec-
tively seek out the tumour cells is identified and the link
between this molecule and the alpha-particle emitter is
chemically established.
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Fig. 1. Experimental thick target yield [9] for the pro-
duction of 211At by (α, 2n) reaction on Bi target. Theo-
retical curve was calculated using the cross-section data
of Ref. [10].
Fig. 2. Comparison of previously published thick tar-
get yield for the 211At production by the (α, 2n) reaction
with the fit to the present experimental points, as pre-
sented in Fig. 1.
TABLE
Thick target yield (TTY) and saturation yield (SY) of
radioisotopes produced by α particle beam
Isotope
Target
chemical
form
Target
thickness
[mg/cm2]
α particle
energy
[MeV]
TTY
[MBq/µAh]
SY
[MBq/µA]
29 37(6) 394(64)
211At 30 46(5) 495(53)
209Bi 98
31 55(7) 591(74)
29 0.009(2) 0.10(2)
210At 30 0.06(1) 0.8(1)
31 0.5(1) 6(1)
72Se
natGeO2 125 30.5
0.26(3) 76(7)
72As 2.8(1) 105(5)
43Sc 98(10) 547(55)
44Sc natCaO 98 31 0.66(3) 3.7(5)
44mSc 0.042(4) 3.6(3)
The 211At isotope is one of the most promising alpha
emitters that could be applied to radionuclide targeted
therapy. However, until now its links to a vector molecule
are still in the research phase, although some preclini-
cal studies have already been published. Our recent re-
sults [5, 8] indicate that we are close to a solution for find-
ing a relatively stable radiopharmaceutical which can at
least be employed externally for glioma cancer treatment.
Production of 211At was started in 2010 and is contin-
uing. In Fig. 1 the thick target production yield [9] of
this isotope, as determined in this work from the cross-
section data [10] via the investigation of its gamma ray
spectrum [11], is shown. Figure 2 compares the results of
the present work with the available data from the liter-
ature. Finally, Table shows the determined thick target
production yield and saturation yield for three bombard-
ing energies. It is worth mentioning here that producing
211At by the (α, 2n) reaction one should avoid the for-
mation of the very dangerous 210At isotope. Therefore,
in Table the yield of this isotope produced by the (α, 3n)
reaction above 29 MeV bombarding energy is also shown.
The activity ratio of these two isotopes was used for the
exact energy determination of the He+ beam. The lower
energy points in Fig. 1 were obtained using Al beam en-
ergy degraders.
4. Positron emitting generator pair 72Se/72As
The 72Se/72As pair is listed in Ref. [12] between rather
long-lived generator pairs where the daughter nucleus,
although also emitting a number of gamma rays, has po-
tential for positron emission tomography techniques in
places where no cyclotron is available and/or rather long
physiological processes are to be investigated. (The con-
sidered pair have half-lives of 8.5 d and 26 h, respec-
tively.) 72Se may be produced by the (p,4n) reaction
on a mono-isotopic 75As target or the (α, 2n) reaction
on a 21% 70Ge target. Although the calculated cross-
section for this reaction extends up to 50 MeV the re-
action threshold is at 18 MeV, and it may be expected
that the use of a 30 MeV alpha particle beam (from e.g.
a C30XP cyclotron) may still produce a sufficient quan-
tity of the mother radioisotope to be applied to the pro-
duction of this generator.
The investigation of the thick target production yield
of this reaction was also motivated by a chemical study of
the 72Se extraction efficiency and purity from a natGeO2
target, irradiated with a 30 MeV alpha particle beam [13].
In addition to the (α, 2n) reaction producing 72Se a
rather similar cross-section was calculated using the EM-
PIRE code [14] for the production of 72As via the (α,pn)
reaction. The thick target production yields and satu-
ration yields of these reactions determined in this study
are presented in Table. The chemical investigation [13]
also indicated a rather pure 72As extraction from the pro-
duced 72Se activity.
A simple calculation indicates that if the irradia-
tion time with this alpha particle energy were 8 h and
the beam intensity 40 µA a 60 MBq EOB (end of
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beam) Se generator could be produced. Again, assuming
100% chemical extraction efficiency, 3 days after EOB a
50 MBq and 15 days after EOB a 20 MBq As activity
could be extracted.
5. Positron emitting 43,44Sc radioisotopes
These two emerging radioisotopes of a similar half-life
(4 h) are expected to replace in some cases the shorter
lived 18F or to be a substitute for 68Ga for some spe-
cial tumours, insensitive to fluorine compounds. 44Sc is
an ideal radioisotope for three photon techniques [15],
where a rather high energy gamma transition is used to
substantially increase the resolution of the PET image,
smeared out due to the positron range.
There is a number of nuclear reactions which lead to
the formation of these radionuclides using medical p/d
cyclotrons and isotopically separated targets. In the
present study an alternative way [16] was investigated
by irradiating a natural CaO target (97% 40Ca) with
the alpha particle beam. This investigation was only
initiated and will be continued during the following
months. The calculated [14] (α,p) reaction on a 40Ca tar-
get has a threshold at 5 MeV, a maximum cross-section
of about 840 mb at 14 MeV and decreases to 340 mb
above 20 MeV. (The maximal calculated cross-section
of (α,n) reaction is only 40 mb and has its maximum
at roughly the same bombarding energy.) Therefore, a
rather pure 43Sc activity would be produced using an
alpha particle energy below 20 MeV. However, 30 MeV
bombarding energy was instead used for the first irradi-
ations, in order to estimate also the 44Sc production rate
on a 42Ca target (0.6% in natural Ca) using the (α,pn)
reaction. The determined thick target yields and satura-
tion yields for the 43Sc and 44Sc radioisotopes are shown
in Table. Figure 3 shows the radionuclidic purity of 43Sc
as a function of time after the EOB.
Fig. 3. Evolution in time of the relative intensities of
Sc isotopes produced during a 4 h irradiation of the
natCaO target with 31 MeV α particle beam.
6. 211At radiopharmaceuticals
Bismuth targets irradiated at HIL were transported
to the Institute of Nuclear Chemistry and Technology
where 211At was isolated from the target by thermochro-
matographic methods. Our studies with 211At have been
directed to obtaining a radiopharmaceutical for the treat-
ment of the residue of glioma cancer cells after brain tu-
mour resection. For the binding of 211At to substance P
(a vector with high affinity to the NK1 receptor on
glioma cells) the following approaches were studied: at-
taching 211At to Rh3+ tetrathioether complexes such as
Rh[16aneS4-diol]
211At [17, 8], the adsorption of 211At on
silver impregnated TiO2 nanoparticles [5] and recently
adsorption on gold nanoclusters and nanoparticles [18].
The radiobioconjugates obtained exhibited good stability
in various biological liquids including human serum and
cerebral spinal fluid. In the short term studies on cell
affinity and radiotoxicity of the obtained radiobioconju-
gates will be performed.
7. Conclusions
The heavy ion cyclotron operating at the Heavy Ion
Laboratory of the University of Warsaw has been ex-
tensively employed in recent years for the production
of medical radioisotopes using the internal He+ beam.
The maximum energy of this beam is 32 MeV and cur-
rently the intensity is of up to 1 pµA. Although this in-
tensity is sufficient for the production of research quan-
tities of these radioisotopes, a more intense beam would
be needed for their production for clinical applications.
An upgrade of the HIL cyclotron and the installation in
the Warsaw area of a new machine accelerating alpha
particles are being considered.
Acknowledgments
The authors warmly thank the HIL cyclotron opera-
tion team for running a number of the beam hours nec-
essary for the research described in this paper and express
their thanks to the students from the University of Sile-
sia for their help during the course of the diploma and
master's studies at the Heavy Ion Laboratory in War-
saw. Discussions with Ulli Koester are also appreciated.
One of the authors (K.S.) is supported through an Dok-
toris project co-financed by EU from the European Social
Fund.
References
[1] J. Jastrz¦bski, Acta Phys. Pol. B 43, 193 (2012).
[2] J. Choi«ski, J. Jastrz¦bski, K. Kilian, I. Mazur,
P.J. Napiorkowski, A. P¦kal, D. Szczepaniak, EPJ
Web of Conferences 66, 10003 (2014).
[3] J. Czub, D. Bana±, A. Bªaszczyk, J. Braziewicz, I. Bu-
raczewska, J. Choi«ski, U. Górak, M. Jaskóªa, A. Ko-
rman, A. Lankoff, H. Lisowska, A. Łukaszek, Z. Sze-
fli«ski, A. Wójcik Appl. Radiat. Isot. 67, 447 (2009).
[4] J. Choi«ski, T. Czosnyka, J. Dworski, J. Jastrz¦bski,
J. Kownacki, E. Kulczycka, J. Kurzy«ski, J. Miszczak,
A. Stolarz, K. Sudlitz, J. Sura, L. Zemªo, Nukleonika
48, S109 (2003).
1474 K. Szkliniarz et al.
[5] E. Leszczuk, M. Łyczko, A. Piotrowska, A. Bilewicz,
A. Stolarz, A. Trzci«ska, K. Szkliniarz, B. W¡s, Ra-
diochim. Acta, in press.
[6] J. Choi«ski, A. Jakubowski, J. Jastrz¦bski, B. Pa-
przycki, A. Pietrzak, R. Ta«czyk, A. Stolarz,
D. Szczepaniak, A. Trzci«ska, J. Chudyka, K. Tworek,
W. Zipper, B. Petelenz, B. W¡s, A. Bilewicz, M. Ły-
czko, HIL Annual Report 2011, Eds. M. Palacz,
N. Keeley, University of Warsaw, Warsaw 2012, p. 52.
[7] A. Stolarz, Nucl. Instrum. Methods Phys. Res. A
397, 114 (1997).
[8] M. Łyczko et al., in preparation.
[9] N.N. Krasnov, Int. J. Appl. Radiat. Isot. 25, 223
(1974).
[10] IAEA, Nuclear Data for the Production of Therapeu-
tic Radionuclides, Vienna 2010.
[11] National Nuclear Data Center
(http://www.nndc.bnl.gov/), 2013.
[12] IAEA, Radioisotopes and Radiopharmaceuticals Se-
ries No. 2, Vienna 2010.
[13] E. Chajduk et al., to be published.
[14] M. Herman, R. Capote, B.V. Carlson, P. Obloºinský,
M. Sin, A. Trkov, H. Wienke, V. Zerkin, NDS 108,
2655 (2007).
[15] P. Thirolf, Acta Phys. Pol. A 127, 1441 (2015).
[16] S. Krajewski, A. Majkowska-Pilip, A. Bilewicz, pri-
vate communication.
[17] M. Pruszy«ski, A. Bilewicz, M.R. Zalutsky, Biocon-
jugate Chem. 19, 958 (2008).
[18] Ł. Janiszewska et al., to be published.
